Ernexa Therapeutics (NASDAQ: ERNA) announced a 1‑for‑25 reverse stock split of its common stock, effective May 4, 2026 at 12:01 a.m. Eastern Time. The split will consolidate each 25 existing shares into one new share, reducing the total number of shares outstanding from approximately 29.15 million to about 1.17 million.
The reverse split is intended to bring the company’s share price back into compliance with Nasdaq’s $1.00 minimum bid‑price rule, thereby preserving its listing on the Nasdaq Capital Market. The move follows a delisting notice received on March 20, 2026 for failing to maintain the minimum bid price, and it comes after a prior 1‑for‑15 reverse split executed on June 12, 2025. By maintaining Nasdaq status, Ernexa keeps access to capital markets and investor visibility, which are critical for funding its clinical development program.
Ernexa’s stock price had fallen below the $1 threshold due to a combination of limited revenue, the preclinical nature of its pipeline, and the need to raise capital to advance its lead candidates, ERNA‑101 and ERNA‑201. The company recently completed a $10.5 million financing and has reduced general and administrative expenses by roughly 61% year‑over‑year in 2025, reflecting a disciplined cost‑control effort. These actions underscore the company’s focus on sustaining operations while it prepares for first‑in‑human trials slated for Q4 2026.
"This is a critical and transformational year for Ernexa as we continue to execute on our strategic priorities and advance our pipeline toward first‑in‑human clinical studies. With key fundamentals now in place, we are positioning the Company for sustained, long‑term success. Maintaining our Nasdaq listing is an important component of that strategy, supporting our ability to access capital, increase visibility and further strengthen engagement with high‑quality, fundamentally focused healthcare investors. We remain committed to delivering on our milestones and creating value for shareholders as we move forward," said Sanjeev Luther, President and CEO. Luther also noted that the coming year represents a transformative period as the company transitions from a preclinical organization into a clinical‑stage biotechnology company.
Investor sentiment has reflected concerns about Ernexa’s financial condition and future outlook, with market participants questioning the company’s ability to achieve its clinical milestones and secure additional funding. The reverse split, while necessary for Nasdaq compliance, highlights the ongoing challenges the company faces in maintaining a share price above the regulatory threshold and underscores the importance of its upcoming clinical and financing milestones for long‑term viability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.